Captisol sales were $21.1 million compared with $9 million in the year-ago quarter. The significant increase was due to higher sales of Captisol to support evaluation of Gilead’s GILD remdesivir as treatment for patients with severe COVID-19. Remdesivir received FDA’s Emergency Use Authorization on May 1 in the United States.
Contract revenues were $2.1 million in the first quarter compared with $11.1 million a year ago.